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Abstract
Francisella tularensis (F. tularensis) has been designated by the CDC as one of the ten organisms
most likely to be engineered for bioterrorism. Symptoms of tularemia in humans are non-specific,
thus making the disease difficult to diagnose. If not quickly diagnosed and treated, the disease has a
high mortality rate - thus methods for early and specific diagnosis are of critical importance.
This immunoaffinity MALDI MS/MS (iMALDI) assay provides unambiguous detection of F.
tularensis peptides at attomole levels from peptide solutions, and at low CFU levels from bacteria.
The addition of stable-labeled versions of the peptide as internal standards allows absolute
quantitation of F. tularensis peptides with a linear dynamic range spanning two orders of magnitude.
The ability of mass spectrometry to obtain amino acid sequence data on affinity-captured peptides
provides absolute specificity and avoids “false positives” from the non-specific binding. The F.
tularensis iMALDI assay has been applied to different samples, such as nasal swabs.
This novel quantitative diagnostic F. tularensis iMALDI assay allows the safe, sensitive and specific
detection of F. tularensis. The assay can be easily adapted to other target peptides and therefore has
broad application potential in clinical diagnosis of other pathogens and diseases.
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1. Introduction
Tularemia is caused by Francisella tularensis (F. tularensis), a small, nonmotile, aerobic
Gram-negative cocco-bacillus. Although normally causing a relatively rare tick-borne disease
in humans, F. tularensis has the potential to be engineered for bioterrorism. The bacteria can
penetrate unbroken skin, can survive and multiply within macrophages, and can then spread
to various organs through the blood [1]. Ten bacteria injected subcutaneously [2], 10-50 on
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contact with unbroken skin [3], 10-50 given by aerosol [4,5], or 102 to108 bacteria by ingestion
[3] are sufficient to cause infection. Humans who have direct physical contact with infected
animals or insects, or have inhaled aerosolized bacteria, have a good chance of becoming
infected. Untreated, the mortality rate can be 30% [6].
Initial non-specific flu-like symptoms usually appear 3 days after exposure [7], and general
laboratory tests (CRP, LDH, alkaline phosphatase, leukocytes, etc.) are insufficient for
diagnosis. Because early antibiotic therapy (with streptomycin or gentamicin) can greatly
reduce the lethality rate [8], an immediate diagnosis of an infection with F. tularensis is critical.
Because of the virulence of F. tularensis, the severity of the disease, the rapidity of progression
from initial onset to seriousness or death, and the high mortality rate, several agencies [9] have
been concerned about the weaponization of F. tularensis, especially the use of aerosolized
bacteria by terrorists as an airborne pathogen [10-12]. F. tularensis has been designated as one
of the organisms most likely to be engineered for bioterrorism [13], and one of the six “category
A bioterrorism organisms” [1,11,14,15].
Bacteriological methods can be used for detecting F. tularensis [16], but culturing the organism
is difficult [2,4,10,17], time-consuming (sometimes taking several days), and is potentially
hazardous to laboratory personnel [18]. Moreover, several studies have shown [19] that the
sensitivities and specificities of these methods are low (note: “specificity” means that there are
no “false positives” - i.e., the test gives a positive result only for the target organism).
Since culturing F. tularensis is difficult, serological tests such as the bacterial
microagglutination (MA) test, have been used to diagnose tularemia, but this takes one week
for measurable levels of antibodies to develop, and an additional week for sufficient antibody
levels for a reliable test [10,20-23]. Antibodies against F. tularensis may cross react with other
organisms such as Brucella, Proteus OX19, and Yersinia spp. [10], which reduces the
specificity and could lead to false positives. More recently, another type of serological test, an
enzyme-linked immunosorbent assay (ELISA), achieved a detection limit of 103 bacteria
mL-1 in PBS and 104 bacteria mL-1 in human serum [24]. However, when samples are
contaminated with other microorganisms [25], accurate diagnosis with ELISA or culturing
methods is very difficult due to their low specificities.
PCR is a molecular method for detection of F. tularensis that usually only takes several hours
per reaction. A hand-held PCR assay could detect F. tularensis in 3 hours, and achieved the
analytical sensitivity of 100 bacteria mL-1 PBS or 103 - 104 bacteria mL-1 serum [26]. However,
PCR may give false positives from contamination with other DNA, which lowers its specificity.
Moreover, simultaneous assaying for multiple species or virulence factors by PCR is difficult
[27].
In this paper, we describe a peptide-based immunoaffinity MALDI mass spectrometry
(iMALDI) assay for detection of F. tularensis, which circumvents many of the problems
associated with traditional detection methods. It is based on capture of the F. tularensis IglC
aa 49-61 peptide. This F. tularensis peptide assay is capable of fast, safe, sensitive, and specific
detection of F. tularensis in PBS solution. It can be used for absolute quantitation of target
peptides and, therefore, for absolute quantitation of their parent proteins. We also demonstrate
the applicability of iMALDI to the detection of F. tularensi in clinical samples, such as human
plasma and nasal swabs.
2. Experimental section
In iMALDI (Figure 1) [28] anti-peptide antibodies are first produced and immobilized on
affinity beads. Next, the proteome of interest is proteolytically digested. Isotopically-labeled
epitope-containing peptides, called “heavy” peptides, are added into the digest as internal
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standards for quantitation. The digest, containing both the labeled “heavy” peptides and the
unlabeled native (“light”) peptides, is incubated with the antibody beads and both types of
peptides are adsorbed. After immuno-adsorption, the antibody-beads are arranged in a
microarray/spot format on the MALDI-target plate. MALDI matrix solution is then added,
which enables the elution of the affinity-bound peptides from the immobilized antibodies
permitting MALDI analysis of the peptides. The relative abundances of the molecular ion
signals corresponding to the original “light” and “heavy” peptides are used for quantification.
Absolute specificity can be achieved by mass spectrometric sequencing of the epitope-
containing peptide, using MALDI-MS/MS.
2.1. Target protein
The 23kDa protein, IglC, from F. tularensis bacteria is encoded by iglC, whose sequence has
no significant homology to any other gene present in the GenBank database [29]. Live Vaccine
Strain (LVS) bacteria, at a concentration of 2.25×109 CFU (Colony Forming Units) mL-1 in
70% ethanol, were used. The total protein concentration of the bacteria sample was 700ng
mL-1 as determined with an ELX800 Universal Microplate Reader.
2.2. Nasal swab samples
Mice were inoculated intranasally with 1 × 105 LVS. Two days post inoculation, a small, moist,
alginate swab was used to rub across the nostrils of the mice. The swab was then swirled in a
tube containing 100 μL PBS. Next, 100 μL of 95% ethanol was added to the sample to ensure
inactivation.
2.3. Tryptic digestion
Digestion of human plasma (UNC blood bank) was carried out in 25mM ammonium
bicarbonate (Sigma) at 37°C overnight. A ∼1:10 enzyme:substrate ratio of trypsin
(Sequencing-grade modified trypsin, Promega) to protein was used. The digested human
plasma was spiked with F. tularensis peptides or a bacterial digest to mimic clinical samples.
Before digestion, the nasal swab solution was diluted with ammonium bicarbonate until the
final concentration of ethanol was 38%, which is compatible with tryptic digestion.
2.4. Antibody production and immobilization of antibodies on beads
Four F. tularensis IglC tryptic peptides, which are absolutely unique to, and thus diagnostic
of F. tularensis, were selected for their high sensitivity in the MALDI-MS mode (Figure 2 and
Table 1). These four peptides were synthesized by Sigma-Genosys. Antibodies were raised
against each peptide, and tested by ELISA to determine the detection sensitivities/efficiencies.
The peptide that showed the highest binding efficiency was selected for use in the
Francisella peptide assay, and the corresponding antibody was purified by Sigma-Genosys.
The anti-peptide antibody was then immobilized on CNBr-activated sepharose beads
(Amersham Pharmacia) according to the manufacturer’s instructions [30]. Briefly, by reacting
with the primary amine groups on the antibody, the sepharose beads covalently linked to the
antibody. Excess binding sites on the beads are blocked by incubation with an amine-containing
buffer, (in this case, Tris). The process was completed by a series of washes at alternating pH.
2.5. Immuno-adsorption protocol
An aliquot of settled antibody-bead slurry (1-5 μL) was added to a compact reaction column
(USB) and washed 4-5 times with 400 μL of 0.1× PBS. A bacterial digest or synthetic F.
tularensis IglC peptide [CNIVAIEGGEDVTK, aa 49-61, calculated MW=1446.71 (note: the
N-terminal cysteine, C, is not part of the native sequence, but was added to facilitate antibody
production)] was dissolved in water/buffer and diluted to a series of concentrations, e.g. 25 ng
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μL-1, 5 ng μL-1, 0.5 ng μL-1, etc. A 20 μL aliquot of each solution was incubated separately
with a small amount (1∼5 μL) of antibody-beads to immuno-adsorb the epitope-containing
peptide. Peptide solutions or a bacterial digest spiked into a plasma digest mixture were used
to mimic clinical samples. Three negative control experiments were performed by incubating
(a) unconjugated agarose beads with PBS; (b) unconjugated agarose beads with synthetic
peptide or bacteria digest sample; and (c) antibody-beads with PBS, respectively.
After incubation for 2-4 h at room temperature with end-to-end rotation on a “Labquake” rotator
(Lab Industries), the beads were washed 6 times with 400 μL of freshly-made 50 mM
ammonium bicarbonate. When high levels of non-specific binding were expected in complex
samples such as plasma, the beads were washed 3 times with 400mM of NaCl (Sigma) followed
by 3 times with 50 mM ammonium bicarbonate. Then the beads were re-suspended in a small
volume of 50 mM ammonium bicarbonate (1-5 μL) and an aliquot of the beads (0.5 μL) was
spotted directly onto the MALDI target as described in the Results and Discussion section.
2.6. Isotopic labeling for absolute quantitation
The F. tularensis IglC aa 49-61 peptide 49NIVAIEGGEDVTK61 (calculated MW=1343.69)
containing an isotopically-labeled valine at position 59 (underlined) (the “heavy” peptide) was
synthesized at the UNC Peptide Synthesis Facility, using a 13C-labeled fmoc Valine purchased
from Isotec/Sigma-Aldrich according to the fmoc approach described in details elsewhere
[31]. The increase in mass from the unlabeled (“light”) F. tularensis IglC aa 49-61 peptide was
6 Da.
2.7. Absolute quantitation
The “heavy” peptide, dissolved in water (HPLC grade, Pierce) was used as an internal standard.
Heavy peptide was spiked into a F. tularensis bacterial digest in various amounts, immuno-
adsorbed on anti-F. tularensis IglC peptide antibody beads, and analyzed by MALDI-MS of
the beads on the MALDI target.
2.8. Mass spectrometric analysis
MALDI-MS experiments were performed on Bruker Daltonics’ (Billerica, MA) Reflex III and
Ultraflex MALDI-TOFs, using Bruker’s Anchor-chip MALDI-target plates (400 or 600 μm/
384 spot format). MS/MS analyses were carried out on an Applied Biosystems Voyager 4700
(Framingham, MA) MALDI-TOF/TOF. The matrix used for all experiments was recrystallized
(from hot methanol) α-cyano-4-hydroxycinnamic acid (HCCA) (Sigma). A saturated solution
of HCCA in 50:49.9:0.1 acetonitrile (Caledon Laboratories): water (HPLC grade, Pierce):
trifluoroacetic acid (Pierce) was used. A small volume (1-5 μL) of ammonium bicarbonate
(ABC) solution (50mM) was added for easy placement of the beads on the MALDI target.
Following placement of the antibody beads on the target, 0.3-0.5 μL of HCCA matrix was
added, and the spot was allowed to dry at room temperature.
3. Results and discussion
The iMALDI technique belongs to a general category of techniques which couples affinity
capture with direct mass spectrometric analysis of target proteins (Experimental section and
Figure 1) [32-49]. In iMALDI, anti-peptide antibodies are immobilized on sepharose beads for
affinity capture, rather than on the surface of a plate, thus eliminating the need for special
surface chemistry. Additional advantages of using affinity beads are less-stringent sample
storage requirements after antibody immobilization, fewer complications resulting from
denaturation of the capture antibody in solution, and the ability to incubate several types of
beads with small volumes of tryptic-digested biological fluid instead of “soaking” the entire
target. Because peptides are more stable and less susceptible to denaturation, the iMALDI
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should be more reproducible from sample to sample than the techniques based on anti-protein
antibodies, and sample storage requirement should not be as stringent.
Unlike conventional affinity capture/elution/MALDI techniques [33,34], the “stable isotope
standards with capture by anti-peptide antibodies” (SISCAPA) approach [35], or on-target
elution followed by removal of affinity beads as was done by Li [50], in iMALDI the affinity
beads are placed directly on the MALDI target and analyzed without prior elution of the bound
analytes [32-49], which greatly reduces the sample loss and therefore increases the detection
sensitivity. In iMALDI, after immuno-adsorption, the antibody beads are arranged in a
microarray/spot format on the MALDI-target plate. Addition of MALDI matrix solution
releases the affinity-bound peptides from the immobilized antibodies permitting MALDI-
analysis of the peptides. Multiple samples can be analyzed simultaneously by mass
spectrometry as an array of different anti-peptide antibody beads on a MALDI target.
Furthermore, since complete inactivation of the bacteria can be achieved by enzymatically
digesting the lysate at the time of sample collection, the iMALDI technique carries low risk to
laboratory personnel.
3.1. Sensitivity
3.1.1. Detection of F. tularensis bacteria in PBS solution—By direct MALDI-MS
analysis of the beads, the detection limit for the synthetic F. tularensis IglC peptide (cysteine
was added for antibody production) was determined to be in the low attomole range (14
attomoles) in buffer (HPLC-grade water or PBS). Without enrichment by iMALDI, in MALDI-
MS analysis, the detection sensitivity of the peptide in buffer was in the low femtomole range
(17 femtomoles) (Figure 3). In the enrichment process, the peptides are bound to antibody
beads, which greatly reduces losses due to adsorption by tubes and tips. Moreover, when
spotted on the target plate, even after elution by the matrix solution, the peptides do not spread
out all over the spot area. Instead, they tend to aggregate at “hot spots”, and when the laser is
focused at these “hot spots”, greatly increased detection sensitivities can be obtained.
The F. tularensis iMALDI assay, based on the anti-F. tularensis IglC, aa49-61 antibody, can
also detect the target F. tularensis peptide from a bacterial digest. The target F. tularensis
peptide was determined in a bacterial digest equivalent to 80 bacteria. The bacteria were
digested and incubated with a small aliquot (1-5 μL) of anti-aa 49-61 NIVAIEGGEDVTK
antibody beads. One tenth of the antibody beads were spotted on the MALDI target plate and
analyzed directly. Although there were signals from some unknown impurities or non-
specifically bound peptides from, for example, the bacterial digest, the target peptide was still
detectable by its mass. The singly-charged, epitope-containing tryptic peptide (aa 49-61
NIVAIEGGEDVTK) from the IglC protein was observed at m/z = 1344.7 (Figure 4). Therefore
the detection limit for bacteria in PBS solution is determined to be 8 CFU bacteria on target
by using 50% of the antibody beads incubated with 50μL of a bacterial solution in PBS, at a
concentration of 320 CFU mL-1, which is as low as the most sensitive detection systems yet
developed [51,52]. It should be noted that 8 CFU does not represent the lowest possible
detection limit in real applications, but is an estimate of the lowest possible detection limit of
our method, as the tryptic digestion of the protein equivalent of 8 CFU might be difficult.
3.1.2. Detection of F. tularensis bacteria in blood—The following detection limits
were determined for the synthetic F. tularensis IglC, aa49-61 and F. tularensis bacteria spiked
into blood samples (plasma): 69 attomoles of the F. tularensis IglC aa49-61 peptide and 800
CFU of bacteria (Figure 5) on target by using 50% of the antibody beads incubated with
125μL of spiked plasma, at a concentration of 1 femtomole mL-1 IglC aa49-61 peptide and
1280 CFU mL-1 bacteria, respectively. Although this method is not as sensitive for the detection
of F. tularensis bacteria in blood as it is for the detection of bacteria in PBS solution, the
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detection limit is still comparable to most ELISA methods [24,53]. However, our technology
has the advantage of greater safety because we are detecting bacterial peptides after the bacteria
have been inactivated by lysis and proteolysis. In addition, our technology has higher
specificity, since tandem mass spectrometry is a molecular approach with sequencing
capabilities to provide absolute identification of the target molecule.
Due to the high virulence of bioterrorism pathogens, high sensitivity is one of the most
important requirements in order to avoid “false negative” results. The sensitivity in plasma
(800 CFU) is lower than in PBS solution (ca. 10 CFU bacteria), may be due to incomplete
digestion and to high levels of non-specific binding of other plasma proteins which can suppress
the ion signal from the target peptide. Optimized sample preparation protocols may alleviate
this problem. In particular, a major advantage of this MS/MS-based technique is that the
proteins which are the source of these non-specifically-bound peptides can be identified from
the MS/MS spectra of their peptides, and depletion protocols can be specifically designed to
remove these proteins prior to digestion and affinity capture of the target peptides [54].
Improved sample preparation protocols, and improvements in mass spectrometric detection
technology, should lead to routine detection sensitivities of ∼10-100 attomoles of peptide.
3.1.3. Detection of F. tularensis bacteria in Nasal swab samples—The current
technique is also usable for nasal swab analyses. Nasal swabs are widely used in clinical tests,
and are a simple and useful method for collecting a wide range of respiratory viruses. The
collection of a nasal swab is easy and painless, and it can easily be performed in remote
locations [55]. In the mouse nasal swab samples collected 2 days after inoculation, a very low
level of target peptide (m/z=1344.7) was detected (Figure 6a). The absence of the signal for
this peptide in the uninfected mouse samples supports these results (Figure 6b). MS/MS was
not performed on the ion at m/z=1344.7 because the ion abundance was below the instrument
threshold for MS/MS acquisition. No bacteria were observed in a culture of the nasal swab
solution from the infected animal (which later developed tularemia), thus demonstrating that
iMALDI could detect F. tularensis at levels too low for successful culturing of the bacteria.
3.2. Specificity
By “specificity” of the assay, we mean that the target peptide is unique to the organism (as
determined by a BLAST search of the peptide sequence). Thus the detection of this peptide,
at the appropriate MW and with the correct sequence is a positive indication of the presence
of F. tularensis. The iMALDI can provide this specificity by combining two molecular
characteristics of the epitope-containing peptides: i) the molecular weight, typically measured
by MALDI-MS within an error of ≤100 ppm and ii) the amino acid sequence, determined by
performing MS/MS on the same sample.
We have demonstrated that this iMALDI technology is able to accurately determine the
molecular weight of an immunoaffinity-enriched F. tularensis peptide from a proteolytic digest
of F. tularensis bacteria in PBS solution and blood. The molecular weight determination was
accurate to within 60 ppm. Sequence information on the affinity-bound peptide was also
obtained by MALDI-MS/MS (Figure 7a). MS/MS analysis produces high-abundance
sequence-specific ions, resulting in an almost complete amino acid sequence of the peptide.
These sequence-specific ions allow confident assignment of the target peptide (Figure 7b).
Using the existing NCBInr database (2006.02.16), searching with only MS data, we retrieved
74,528 hits out of more than 3 million entries; in contrast, searching with combined MS and
MS/MS data, resulted in only one hit. This demonstrates the specificity of this iMALDI
technique for detecting F. tularensis. Here, we used polyclonal antibodies because of their
ready availability. Polyclonal antibodies often contain more than a single epitope within a
particular stretch of amino acids, and therefore, are able to capture even modified peptides
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since they are likely to contain an unmodified stretch of amino acids. This makes this detection
method tolerant of small sequence variations. On the other hand, the use of polyclonal
antibodies might lead to cross-reactivity with peptides from other species. This could decrease
specificity and/or the detection limit of our method. This issue could be resolved by using a
several monoclonal antibodies, or perhaps even both types of antibodies, for the final clinical
version of this technique.
3.3. Quantitation
Mass spectrometry is well suited for peptide/protein quantitation. MS can perform relative
quantitation using reference peptides from two different samples that have been differentially-
labeled with stable isotopes, or absolute quantitation if a known amount of a stable-isotope
labeled peptide has been added as an internal standard.
To determine the absolute concentration of a given peptide in a sample, and, therefore, the
absolute concentration of the original protein, as is done in isotope dilution-mass spectrometry
(ID-MS) [56], synthetic stable-isotopically labeled “heavy” peptide is used as an internal
standard. These heavy peptides are identical in amino acid sequence to the native epitope-
containing “light” peptides from the protein in the sample, but are higher in mass. They are
added to the proteolytically-digested protein sample prior to incubation with the immobilized
anti-peptide antibody. Following incubation, MALDI-MS analysis of the antibody beads
shows doublets of ion signals from the “light” and “heavy” peptides. The relative abundances
of the molecular ion signals corresponding to the “light” and “heavy” peptides are used to
quantify the amount of the “light” peptide and therefore its parent protein in the original sample.
For quantifying F. tularensis IglC protein, the F. tularensis IglC aa 49-61
peptide 49NIVAIEGGEDVTK61 was synthesized with an isotopically-labeled valine at
position 59 (underscored). This “heavy” peptide (H) is identical in amino acid sequence to the
native epitope-containing “light” peptide (L), but is 6 Da higher in mass (m/z=1350.7) due to
6 13C’s in place of 6 12C’s. In these experiments, the heavy peptide was added in various
amounts (100 femtomoles - 5 picomoles) to a proteolytic digestion of F. tularensis bacteria in
PBS solution, and was immuno-adsorbed using the anti-F. tularensis IglC aa49-61 antibody
immobilized on affinity beads (Figure 8a-d). Analysis of an aliquot of these beads spotted
directly on the MALDI target reveals monoisotopic protonated molecular ions from the two
peptides, separated by 6 Da. Figure 8e shows a linear correlation (R2=0.9988) between the
ratio of the two peptides (H/L) and the amount of H spiked in as internal standard over near
two orders of magnitude (from 100 femtomoles to 5 picomoles). The nearly perfect linear
correlation demonstrates the stability of iMALDI for the absolute quantitation of F.
tularensis peptides using an internal standard.
Compared to the traditional culturing method and microagglutination (MA) test [2,4,10,17,
20-23], iMALDI is more rapid, sensitive and specific. The peptide sequencing capability of
tandem mass spectrometry in iMALDI provides higher molecular specificity than ELISA. The
sensitivity of iMALDI is comparable to the most sensitive PCR method [26], but may not be
as rapid when the digestion and incubation time is considered. However, the digestion time of
iMALDI can be greatly reduced by using immobilized trypsin [57], and the incubation time
can be reduced by using an antibody with high affinity. Moreover, compared to other methods,
iMALDI has higher safety, better absolute quantitation capabilities, and improved high-
throughput analysis capability which significantly reduce the cost per sample. One major
disadvantage of iMALDI is that its overall quality highly depends on the affinity and specificity
of the antibody. However, this problem should be able to be solved by using different strategies
of antibody optimization, or alternative affinity-capture materials such as aptamers [58,59].
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We have shown that the combination of two mass spectrometric approaches (MALDI-MS and
MALDI-MS/MS), inherent in our iMALDI approach, can unambiguously identify affinity-
bound peptides, and therefore, permits specific detection of F. tularensis bacteria. The F.
tularensis iMALDI can detect F. tularensis bacteria in PBS solution at a sensitivity of better
than 10 CFU of bacteria. Since both the molecular weight and the sequence of the bacterial
peptide is determined at high accuracy, the high sensitivity of this technique means a low rate
of “false negatives”, and the high specificity means a low rate of “false positives”. In addition,
the iMALDI F. tularensis peptide assay is adequate for accurate and absolute quantitation of
the target protein concentration. With the addition of robotic liquid handling systems, it would
be an even safer technique, as well as being capable of high-throughput analyses. This would
make iMALDI an extremely valuable tool for the early detection of F. tularensis and other
bioterrorist agents.
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Figure 1. Analytical scheme of the iMALDI assay
Epitope-containing peptides, 49NIVAIEGGEDVTK61, synthesized using isotopically-labeled
amino acid V, are added to the proteolytic digest of F. tularensis bacteria and are subsequently
incubated with the anti-aa49-61 (F. tularensis IglC) antibody beads to immunoadsorb both
isotopically-labeled and unlabelled peptides. After immunoadsorption of the differentially-
labeled peptides, the antibody beads are arranged in a microarray/spot format on the MALDI-
target plate. MALDI matrix solution added to the affinity-bound peptides elutes the peptides
from the immobilized antibodies, permitting MALDI analysis of the peptides. The relative
abundances of the molecular ion signals corresponding to heavy (isotopically-labeled) and light
(unlabelled) peptides are used to quantify the amount of this protein in the original sample.
Absolute specificity can be achieved by mass spectrometric sequencing of the epitope-
containing peptide, using MALDI-MS/MS.
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Figure 2. Selection of F. tularensis IglC peptides for raising antibodies to be used for the F.
tularensis iMALDI assay
MALDI-MS of proteolytic F. tularensis IglC peptides obtained by in-solution digestion of IglC
with trypsin. Four “true” (C-terminal cleavage of K or R residues) tryptic peptides of IglC
(shown in blue) were selected for antibody production based on the high sensitivity in the
MALDI-MS.
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Figure 3. Detection sensitivity of synthetic F. tularensis IglC peptides in solution and using the F.
tularensis iMALDI assay
MALDI-MS spectrum of synthetic F. tularensis IglC peptide CNIVAIEGGEDVTK a) in
solution: a-1) 100 femtomoles; a-2) 1 femtomoles; a-3) 10 attomoles. b) affinity-bound to anti-
aa 48-61 (F. tularensis IglC) antibody beads: b-1) 138 femtomoles; b-2) 1.38 femtomoles; b-3)
13.8 attomoles.
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Figure 4. Detection of F. tularensis bacteria in PBS solution using the F. tularensis iMALDI assay
MALDI-MS spectrum of peptides obtained after proteolysis of F. tularensis bacteria in PBS
solution, affinity-bound to anti-aa49-61 (F. tularensis IglC) antibody beads. The singly-
charged epitope-containing tryptic peptide (aa 49-61 F. tularensis IglC protein) is observed at
m/z = 1344.7 (see inset). The spectrum represents the amount of IglC peptide equivalent to 8
CFU for F. tularensis bacteria.
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Figure 5. Detection of F. tularensis bacteria in plasma samples using the F. tularensis iMALDI assay
MALDI-MS spectrum of peptides obtained after proteolysis of F. tularensis bacteria being
spiked in plasma digest, affinity-bound to anti-aa49-61 (F. tularensis IglC) antibody beads.
The singly-charged epitope-containing tryptic peptide (aa 49-61 F. tularensis IglC protein) is
observed at m/z = 1344.7 (see inset). The spectrum represents the amount of IglC peptide
equivalent to 800 CFU for F. tularensis bacteria.
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Figure 6. Detection of F. tularensis bacteria in nasal swab samples using the F. tularensis iMALDI
assay
a) MALDI-MS spectrum of peptides affinity-bound to anti-aa49-61 (F. tularensis IglC)
antibody beads, obtained after proteolysis of mouse nasal swab extracts collected two days
after the mice were inoculated with F. tularensis. The singly-charged, epitope-containing,
tryptic peptide, NIVAIEGGEDVTK, corresponding to aa 49-61 of the F. tularensis IglC
protein, was observed at m/z = 1344.7 (see inset). b) MALDI-MS spectrum of anti-aa 49-61
(F. tularensis IglC) antibody beads obtained after proteolysis of nasal swab extracts collected
from uninfected mice on the same day.
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Figure 7. Highly specific detection of F. tularensis bacteria in PBS solution by mass spectrometric
sequencing of the immunoaffinity-enriched F. tularensis IglC aa49-61 peptide, using the F.
tularensis iMALDI assay
a) MALDI-MS/MS spectrum of the peptide at m/z = 1344.7 affinity-bound to anti-aa49-61(F.
tularensis IglC) antibody beads, obtained after proteolysis of F. tularensis bacteria in PBS
solution. All of the abundant ions can be assigned to sequence-specific y- and b-ions of the F.
tularensis IglC peptide aa49-61, resulting in unambiguous identification of the
immunoaffinity-enriched peptide. b) This table shows the mass accuracies of the fragment
ions, demonstrating that the assignment of these ion signals is correct. This therefore
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demonstrates that, using our F. tularensis iMALDI assay, F. tularensis bacteria can be detected
with high specificity and correspondingly low “false positive” rates.
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Figure 8. Quantitation of F. tularensis bacteria using the F. tularensis iMALDI assay
Absolute quantitation of the IglC peptide NIVAIEGGEDVTK (aa 48-61) (L, light peptide, m/
z = 1344.7) in a bacterial sample. F. tularensis bacteria were digested and incubated with
different amounts of heavy peptides (H, m/z =1350.7) as internal standards: a) 0.1 picomoles,
b) 0.5 picomoles, c) 1 picomoles, d) 5 picomoles, e) Plot of the observed ratios of monoisotopic
abundances of H and L in the MALDI-MS spectra (a-d) versus the absolute amount of H added.
Note, only a 10% aliquot has been used for the analysis.
Jiang et al. Page 19

























Jiang et al. Page 20
Table 1
Affinity determination of the four anti-(F. tularensis IglC) peptide antibodies against their epitope peptide by
ELISA. The cysteine residue marked with asterisk has been added to the native sequence because of ease of
conjugation with the carrier protein
Tryptic F.t. p23 peptides used antibody
production Anti-(F.t. p23) peptide Antibodies ELISA response (titer)
153AFSISIEPTELMGVS167 [(F.t. p23) aa153-167] 1/50,000
8QQVTSGETIHVR19 [(F.t. p23) aa8-19] 1/3,000
48C*NIVAIEGGEDVTK61 [(F.t. p23) aa48-61] 1/500,000
62ADSATAAASVIR73 [(F.t. p23) aa62-73] 1/10,000
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